CSCI heads into May with a striking split: the stock has more than doubled in a month, while short sellers are steadily rebuilding positions and the company prepares to exit US public reporting obligations.
The price move is the first thing to understand. CSCI closed at C$2.67 on April 28, up 123% over the past month and a further 2.7% on the day — an extraordinary run for a micro-cap Canadian biotech. The rally has come despite a week-on-week slip of 2.6%, which may reflect some profit-taking after the burst higher. What drove the surge is partly explained by the clinical backdrop: Mocertatug Rezetecan, the company's lead candidate, showed a high objective response rate in ovarian and endometrial cancer in data published mid-April, providing the most tangible catalyst the stock has seen in some time.
Short positioning tells a quietly more active story than the headline SI figure alone suggests. Short interest has climbed 40% over the past week and 54% over the past month, reaching the equivalent of roughly 0.05% of the free float — a very small absolute level, but the direction of travel is clear. Borrowing costs have edged higher alongside the build, rising 16% week-on-week to 3.34% annualised, after spending much of March and early April well below that level. Availability in the lending pool is mid-range: around 46% of already-borrowed shares remain available for new borrows, down from 56% a day earlier and well below the 52-week high of 72%. The borrow market is tightening as the short position grows, though it has not yet approached squeeze territory. Days to cover remain low at one day, meaning the position can be unwound quickly if needed.
The most newsworthy structural development is CSCI's stated plan to suspend its US public company reporting obligations, disclosed on April 20. The company filed an SC 13E3 — a going-private-style transaction form — with the SEC on the same day. Peter Puccetti, the largest disclosed holder with around 15,700 shares representing 0.49% of the company, also filed an amended Schedule 13D on April 17, signalling active engagement around this process. The US deregistration removes a layer of regulatory overhead for what is primarily a TSX-listed name, but it also narrows the investor base that can easily access the stock, a factor worth watching for liquidity.
Earnings reactions at CSCI have been consistently negative on the day of the event. The four most recent results announcements produced same-day moves of -29%, -14%, -9%, and -8%, respectively. The next earnings event is scheduled for May 12. That pattern does not imply a repeat, but it does mean the stock enters the print with a track record of sharp downside moves on results days — notable given the 120%-plus run that would provide scope for profit-taking.
With the May 12 earnings date approaching and the US reporting suspension process underway, the stock's behaviour around that print — and any further clinical data releases for Mocertatug Rezetecan — will be the key tests of whether the recent rally attracts lasting conviction or meets the same pattern of post-results selling seen across all four prior events.
See the live data behind this article on ORTEX.
Open CSCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
